The unpredictable nature of flare-ups in fibrodysplasia ossificans progressiva (FOP)
From soft-tissue to bone: Clinical presentation of fibrodysplasia ossificans progressiva (FOP)
Biosimilars: an option to alleviate the heavy burden of immune-mediated inflammatory diseases
Clinical value beyond price alone: anti-TNF biosimilars enable early treatment
Clinical value beyond price alone: biosimilars improve patient access to treatment
Long-term topical management of psoriasis: the road ahead
Over the horizon: early stage trials for NASH
Phase II trials and stem cell therapies
The next global epidemic
The latest treatments in NASH
The future of organ transplantation
Complications of stem cell transplants
Treating rejection in organ transplants
Challenges in transplant organ rejection
Biologic efficacy for complications associated with moderate-to-severe psoriasis
Moderate-to-severe psoriasis: treatment for young women
Migraine treatments: On the horizon
An independent review of current treatments for migraine
Migraine: The forgotten epidemic?
NEW: Moderate to Severe Asthma Learning Zone launches on Medthority.com
Senolytics: Can we treat age-related diseases with a single drug
Long-term disease control in Psoriasis: announcing a new project
Senolytics: an emerging therapeutic for the prevention and treatment of cardiovascular disease
Targeted therapies in triple negative breast cancer
Targeted therapies in HER2 negative breast cancer
Targeted therapies in HER2 positive breast cancer
Breast Cancer- Targeted therapies
World Congress of Dermatology 2019 - A new ERA for global Dermatology
Opioids - Over the horizon
Opioids: The war on drugs
Opioids: the future and challenging the epidemic
Moderate-to-severe psoriasis: the disease burden and unmet needs in different patient groups
Replacement therapies for opioid drugs in pain treatment
Microbiomes: is there nothing that they can't do?
Shaken not stirred your bacteriophage cocktail
From Acne to Immunotherapy: new applications for FMT (Faecal Microbiota Transplantation)
Part Four | Obesity, Type 2 diabetes and cardiovascular disease: Finding the magic bullet
Part Three | Next generation obesity therapies
Part two | New hopes for treatment in the global obesity epidemic
Part One | The effects of obesity and the links to diabetes and cardiovascular disease: now and in the future
Key findings from the SWIPE study
COPD experts tackle key topics in our latest Q&A
Your guide to IBD novel treatments and assessment tools
Immobility and sleep disruption in the ICU - Latest recommendations
UPDATE: Urticaria e-learning new modules & symposia highlights
Unravelling the microbiome - health through happy communities
Psoriasis Knowledge Centre relaunches on Medthority.com
Atopic Dermatitis Knowledge Centre launched on Medthority.com
Reformulation of postnatal haemorrhage prophylaxis could save thousands in lower income countries
Medical cannabis - a novel approach to pain control
Accredited CME: The future of urticaria - advances in CSU research - launched to Medthority.com
New inflammatory bowel disease (IBD) Knowledge Centre
New rare disease platform launched for Hunter Syndrome
New publication digest and infographic for Cardiologists.
Genetic variation and drug efficacy - could this pave the way for personalised medicines?
Neue Informationsmaterialien in deutscher Sprache zum Management von Schmerzen, Agitation und Delir auf der Intensivstation (in Zusammenarbeit mit Orion Pharma)
New: Symposium videos & presentations for immunologists, dermatologists and allergists
Magnetic nanoparticles could help rejuvenate damaged hearts
New findings may pave the way for novel HIV drugs
Adoptive T cell therapy, advanced melanoma and survival
Appetite and the brain - white matter integrity to blame?
Vitamin D in pregnancy - is it any good?
How close are we to a disease-modifying treatment for Alzheimer’s?
Japan's aging population and Alzheimer's
Focus on Primary Care - helping GPs diagnose, manage and treat urticaria
Prof Vincent interview - Defining the eCASH Concept in PAD Management
Inactivity in the elderly increases their cardiovascular risk by 14%
Close social relationships may slow cognitive decline
Type 2 diabetes risk may be increased by statin use in susceptible individuals
Improving non-alcoholic steatohepatitis care – is the finishing line in sight?
Acute myeloid leukaemia: Hope for new treatments
Left ventricular assist devices – A viable therapeutic option for heart failure?
Antibody-drug conjugates (ADCs)
Horizons: a series of opinion & insight articles on disruptive healthcare in practice
The way ahead for cystic fibrosis
Schizophrenia: challenges in a crowded market
Nonalcoholic steatohepatitis: the next global epidemic?
Launch of LAL-Deficiency Knowledge Centre
Latest updates to the Chronic Spontaneous Urticaria Knowledge Centre
Launch of Oral Anticoagulation Reversal Knowledge Centre
SGLT2 Inhibitors: good news for diabetes
Will Glucagon-like peptide-1 agonists dominate the Type 2 Diabetes market?
Launch of Chronic Spontaneous Urticaria CME activity
Launch of new Cystic Fibrosis Knowledge Centre
Launch of new Chronic Lymphocytic Leukaemia CME
Launch of updated Hypogonadism Knowledge Centre
New approaches to anticoagulant therapy
ESOT 2015 speaker slides added to AIKN-IFI
New type 2 diabetes CME activity now available on Medthority.com
ATS 2015 symposium materials added to COPD Knowledge Centre
WCD 2015 videos added to the Chronic Spontaneous Urticaria (CSU) Knowledge Centre
Case studies added to Chronic Spontaneous Urticaria (CSU) Knowledge Centre
New hyperammonaemia resource developed for Medthority.com users
Chronic myelogenous leukaemia: a remarkable success story
Bedwetting resource receives a mobile-friendly transformation
IL-17A treatment section added to Psoriasis Knowledge Centre
Free haemato-oncology report added to AIKN-IFI congresses section
Parkinson's disease: the struggle to control symptoms
FDA approval for Cibinqo to treat adults living with refractory, moderate-to-severe atopic dermatitis.- Pfizer
Positive top-line results of Pfizer’s phase III study exploring co-administration of Prevnar 20 with Pfizer-BioNTech COVID-19 Vaccine in older adults released
Roche launches the cobas pulse system, an industry first professional blood glucose management solution with mobile digital health capabilities to improve patient care.
New Vaxzevria data further support its use as third dose booster.
Publication of new Aveed data in Journal of Clinical Pharmacology; data evaluates dosing flexibility in men with hypogonadism.
Zai Lab announces first patient treated in Greater China in PANOVA-3 phase III pivotal trial.
Arrowhead Pharmaceuticals initiates phase III PALISADE study of ARO-APOC3.
Medtronic announces approval of the Evolut PRO TAVR system in China to treat severe aortic stenosis.
Korsuva injection achieves positive topline results in phase III clinical study in Japan for the treatment of pruritus in hemodialysis patients.
Sandoz submits BLA for proposed biosimilar trastuzumab to FDA.
Intercept Pharma provides update on Phase III REVERSE trial of OCA for compensated cirrhosis due to NASH.
Lebrikizumab + topical corticosteroids demonstrated in a third phase III study ,significant skin improvement and itch relief in people with atopic dermatitis.
Moderna announces preliminary booster data and updates strategy to address Omicron variant of COVID 19.
EMA issues advice on use of Paxlovid (PF-07321332 and ritonavir) for the treatment of COVID-19.
FDA approves Otezla for the treatment of patients with plaque psoriasis regardless of severity level.
Saphnelo recommended for approval by CHMP for the treatment of patients with systemic lupus erythematosus.
Eisai enters an agreement with Gilead Sciences to commercialise filgotinib in Asia.
Primary endpoint met statistical significance in corrected topline efficacy data of phase III ROMAN trial of avasopasem.
Ipsen and GENFIT enter into exclusive licensing agreement for elafibranor.
A panel of US experts has voted unanimously to recommend the Pfizer and Moderna Covid-19 vaccines over Johnson & Johnson's.
Novartis provides an update on phase III ligelizumab studies in chronic spontaneous urticaria (CSU).
FDA grants accelerated approval for Tarpeyo to reduce proteinuria in IgA nephropathy.
CHMP opinion positive for Lorviqua as first-line treatment for ALK-positive advanced NSCLC.- Pfizer Inc.
FDA approval of Vyvgart (efgartigimod alfa-fcab)in generalized myasthenia gravis .- Zai Lab and argenx.
FDA priority review of BLA for eli-cel gene therapy for cerebral adrenoleukodystrophy (CALD) in patients without a matched sibling donor.- bluebird bio.
Immatics and BMS enter into global exclusive license for Immatics’ TCR Bispecific Program IMA 401.
EU approves Xevudy for COVID-19.- GSK + Vir Biotechnology
Antiplatelet therapy in ACS: Choices and Controversies
Anticoagulation Therapy for Stroke Prevention
Respiratory Syncytial Virus (RSV) in Adults
Chronic Kidney Disease Learning Zone
Molecular diagnostics for RET inhibition in NSCLC and thyroid cancers
Hidradenitis suppurativa (HS) Learning Zone
Chronic Spontaneous Urticaria Learning Zone
Multiple Sclerosis (MS) Learning Zone
Food Allergy Learning Zone
Atopic Dermatitis Learning Zone
Cardiovascular Metabolism Learning Zone
Major depressive disorder and treatment-resistant depression
Inflammatory Bowel Disease Learning Zone
Transplantation Learning Zone
Innovations in MS care to improve individual disease management
Diagnosis and management of primary hyperoxaluria type 1
Improving treatment options for childhood psoriasis
CDK4/6 inhibitors in breast cancer
Managing Osteoarthritis-associated Pain
Fluid Management Learning Zone
Optimising anti-TNF treatment using biosimilars
Fibrinogen Deficiency in Bleeding Learning Zone
Idiopathic Pulmonary Fibrosis
Oral Anticoagulation Reversal Learning Zone
Psoriasis Learning Zone
Sleep Apnea Learning Zone
Hereditary ATTR Amyloidosis
One Neuroscience and Pain Learning Zone
Acute Hepatic Porphyria Learning Zone